Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Published on Aug 21, 2013in The New England Journal of Medicine74.699
· DOI :10.1056/NEJMOA1215734
Brian G. Feagan115
Estimated H-index: 115
(UWO: University of Western Ontario),
Paul Rutgeerts167
Estimated H-index: 167
(Katholieke Universiteit Leuven)
+ 13 AuthorsAsit Parikh18
Estimated H-index: 18
(Takeda Pharmaceutical Company)
Sources
Abstract
We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 pa tients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, with disease evaluation at week 6. In the trial of maintenance therapy, patients in either cohort who had a response to vedolizumab at week 6 were randomly assigned to continue receiving vedolizumab every 8 or 4 weeks or to switch to placebo for up to 52 weeks. A response was defined as a reduction in the Mayo Clinic score (range, 0 to 12, with higher scores indicating more active disease) of at least 3 points and a de crease of at least 30% from baseline, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. Results Response rates at week 6 were 47.1% and 25.5% among patients in the vedolizumab group and placebo group, respectively (difference with adjustment for stratification factors, 21.7 percentage points; 95% confidence interval [CI], 11.6 to 31.7; P 1), as compared with 15.9% of pa tients who switched to placebo (adjusted difference, 26.1 percentage points for vedoliz umab every 8 weeks vs. placebo [95% CI, 14.9 to 37.2; P<0.001] and 29.1 percentage points for vedolizumab every 4 weeks vs. placebo [95% CI, 17.9 to 40.4; P<0.001]). The frequency of adverse events was similar in the vedolizumab and placebo groups. Conclusions Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis. (Funded by Millennium Pharmaceuticals; GEMINI 1 ClinicalTrials.gov number, NCT00783718.)
Figures & Tables
Download
📖 Papers frequently viewed together
563 Citations
545 Citations
1,735 Citations
References38
Newest
#1Yongjun Wang (UWO: University of Western Ontario)H-Index: 4
#2Claire E Parker (Cochrane Collaboration)H-Index: 22
Last. John K MacDonald (Cochrane Collaboration)H-Index: 43
view all 5 authors...
Background Oral 5-aminosalicylic acid (5-ASA) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. Previously, it was found that 5-ASA drugs in doses of at least 2 g/day, were more effective than placebo but no more effective than SASP for inducing remission in ulcerative colitis. This updated review includes more recent studies and evaluates the efficacy and safety of 5-ASA preparations used for the treatment of mild to mode...
384 CitationsSource
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
Last. Asit Parikh (Millennium Pharmaceuticals)H-Index: 18
view all 17 authors...
BackgroundUstekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn’s disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy. MethodsWe randomly assigned patients to receive a single intravenous dose of ustekinumab (either 130 mg or approximately 6 mg per kilogram of body weight) or placebo in two induction trials. The UNITI-1 trial ...
1,629 CitationsSource
#1Krista G. Haanstra (Biomedical Primate Research Centre)H-Index: 17
#2Sam O. Hofman (Biomedical Primate Research Centre)H-Index: 10
Last. Eric R. Fedyk (Millennium Pharmaceuticals)H-Index: 15
view all 10 authors...
The immune system is characterized by the preferential migration of lymphocytes through specific tissues (i.e., tissue tropism). Tissue tropism is mediated, in part, by the α4 integrins expressed by T lymphocytes. The α4β1 integrin mediates migration of memory T lymphocytes into the CNS, whereas the α4β7 integrin mediates migration preferentially into gastrointestinal tissue. This paradigm was established primarily from investigations in rodents; thus, the objective of this investigation was to ...
83 CitationsSource
#1Neal Shahidi (UBC: University of British Columbia)H-Index: 15
#2Yi-Tzu Nancy Fu (UBC: University of British Columbia)H-Index: 2
Last. Brian Bressler (UBC: University of British Columbia)H-Index: 29
view all 4 authors...
Background: Guidelines mandate screening for latent tuberculosis infection (LTBI) prior to anti-tumor necrosis factor (anti-TNF) therapy in patients with inflammatory bowel disease (IBD). However, many are already on immunosuppressive therapy (IST) that may affect the precision of the Tuberculin skin test (TST). Our aim was to assess the performance of the new interferon-gamma release assays (IGRAs) to detect LTBI in patients with IBD. Methods: MEDLINE and EMBASE were searched (up to June 2011) ...
51 CitationsSource
#1Eric R. Fedyk (Takeda Pharmaceutical Company)H-Index: 15
#2Tim Wyant (Takeda Pharmaceutical Company)H-Index: 21
Last. V Kadambi (Takeda Pharmaceutical Company)H-Index: 5
view all 7 authors...
Background: Biological therapies that antagonize specific molecules have demonstrated efficacy in inflammatory bowel diseases, but infections resulting from systemic immunosuppression underscore the need for safer therapies. The objective of this investigation was to determine if antagonism of the α4β7 integrin would exclusively yield gut-selective antiinflammatory activity in primates. Methods: A series of experiments were conducted to investigate potential intra- and extraintestinal effects in...
97 CitationsSource
#1Gary Bloomgren (Biogen Idec)H-Index: 9
#2Sandra RichmanH-Index: 11
Last. Carmen BozicH-Index: 11
view all 11 authors...
Background Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or absence of three risk factors: positive status with respect to anti–JC virus antibodies, prior use of immunosuppressants, and increasing duration of natalizumab treatment. Methods We used data from postmarketing sources, clinical studies, and an independent Swedish registry to estimate the incidence o...
957 CitationsSource
#1Nicholas SchwabH-Index: 23
#2Jochen C. Ulzheimer (University of Würzburg)H-Index: 7
Last. Heinz Wiendl (WWU: University of Münster)H-Index: 86
view all 14 authors...
Objectives: Progressive multifocal leukoencephalopathy (PML) has become much more common with monoclonal antibody treatment for multiple sclerosis and other immune-mediated disorders. Methods: We report 2 patients with severe psoriasis and fatal PML treated for ≥3 years with efalizumab, a neutralizing antibody to αLβ2-leukointegrin (LFA-1). In one patient, we conducted serial studies of peripheral blood and CSF including analyses of leukocyte phenotypes, migration ex vivo, and CDR3 spectratypes ...
84 CitationsSource
#1Alexander C. Ford (LGI: Leeds General Infirmary)H-Index: 86
#2Khurram J. Khan (McMaster University)H-Index: 13
Last. Paul Moayyedi (McMaster University)H-Index: 115
view all 4 authors...
Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis
104 CitationsSource
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Gert Van Assche (Katholieke Universiteit Leuven)H-Index: 92
Last. Roopal ThakkarH-Index: 23
view all 10 authors...
Background & Aims Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor (TNF)-α. Its efficacy as maintenance therapy for patients with ulcerative colitis has not been studied in a controlled, double-blind trial. Methods Ulcerative colitis long-term remission and maintenance with adalimumab 2 (ULTRA 2) was a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of adalimumab in induction and maintenance of clinical remission in 494 patients with mo...
821 CitationsSource
#1Catherine Milch (Millennium Pharmaceuticals)H-Index: 16
#2Tim Wyant (Millennium Pharmaceuticals)H-Index: 21
Last. I. Fox (Millennium Pharmaceuticals)H-Index: 15
view all 6 authors...
9 CitationsSource
Cited By1523
Newest
#1Nicola Wyatt (Newcastle University)H-Index: 1
#2R. Alexander Speight (Newcastle University)H-Index: 1
Last. Christopher A Lamb (Newcastle University)H-Index: 23
view all 5 authors...
In the last two decades, understanding of inflammatory bowel disease (IBD) immunopathogenesis has expanded considerably. Histopathological examination of the intestinal mucosa in IBD demonstrates the presence of a chronic inflammatory cell infiltrate. Research has focused on identifying mechanisms of immune cell trafficking to the gastrointestinal tract that may represent effective gut-selective targets for IBD therapy whilst avoiding systemic immunosuppression that may be associated with off-ta...
Source
#1Sudheer K. Vuyyuru (AIIMS: All India Institute of Medical Sciences)H-Index: 3
#2Saurabh Kedia (AIIMS: All India Institute of Medical Sciences)H-Index: 21
Last. Vineet Ahuja (AIIMS: All India Institute of Medical Sciences)H-Index: 39
view all 10 authors...
Aim: We conducted this network meta-analysis to compare the efficacy and safety of targeted pharmacotherapies and fecal microbial transplantation (FMT). Patients & methods: Nineteen studies were included and there was only one head-to-head randomized controlled trial (adalimumab vs vedolizumab). Results: All interventions, including FMT, were superior to a placebo in inducing clinical remission (except adalimumab - odds ratio 1.66; 95% CI: 0.97-2.85), clinical response and endoscopic remission. ...
Source
#1Kevin J. RobertsH-Index: 29
#2Marion F. CubittH-Index: 4
Last. Keith P. RayH-Index: 3
view all 13 authors...
Anti-TNFα and anti-IL-23 antibodies are highly effective therapies for Crohn’s disease or ulcerative colitis in a proportion of patients. V56B2 is a novel bispecific domain antibody in which a llama-derived IL-23p19-specific domain antibody, humanised and engineered for intestinal protease resistance, V900, was combined with a previously-described TNFα-specific domain antibody, V565. V56B2 contains a central protease-labile linker to create a single molecule for oral administration. Incubation o...
Source
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation of the large intestine. The severity of UC is often represented by the Mayo Endoscopic Subscore (MES) which quantifies mucosal disease activity from endoscopy videos. In clinical trials, an endoscopy video is assigned an MES based upon the most severe disease activity observed in the video. For this reason, severe inflammation spread throughout the colon will receive the same MES as an otherwi...
#1Michele Francesco Chiappetta (UNIME: University of Messina)
#2Anna Viola (UNIME: University of Messina)H-Index: 6
Last. Giuseppe Costantino (UNIME: University of Messina)H-Index: 15
view all 18 authors...
Efficacy and safety of ustekinumab for the treatment of ulcerative colitis (UC) has been demonstrated in clinical trials, but few real-world data are available so far. The aim of this study was to ...
Source
#2Shuhua TianH-Index: 1
Last. Xiangfei Li (NAU: Nanjing Agricultural University)
view all 9 authors...
Inflammatory bowel disease (IBD), which significantly affects human health, has two primary presentations: Crohn’s disease and ulcerative colitis (UC). Highland barley is the most common food crop for Tibetans and contains much more β-glucan than any other crop. Highland barley β-glucan (HBBG) can relieve the gastrointestinal dysfunction and promote intestines health. This study aimed to evaluate whether HBBG can relieve UC in mice. A mouse model of UC was established by adding 2% dextran sulfat...
Source
#1Ho-Sup Lee (UCSD: University of California, San Diego)H-Index: 4
#2Hao Sun (UCSD: University of California, San Diego)H-Index: 56
Last. Mark H. Ginsberg (UCSD: University of California, San Diego)H-Index: 145
view all 7 authors...
Rap1 GTPase drives assembly of the Mig10/RIAM/lamellipodin–Integrin–Talin (MIT) complex that enables integrin dependent lymphocyte functions. Here we used tandem affinity tag based proteomics to isolate and analyze the MIT complex and reveal that Phostensin (PTSN), a regulatory subunit of protein phosphatase 1, null is a component of the complex. PTSN mediates dephosphorylation of Rap1 thereby preserving the activity and membrane localization of Rap1 to stabilize the MIT complex. CRISPR/Cas9-ind...
Source
Source
Infliximab and vedolizumab are effective treatments for inflammatory bowel disease (IBD), although associated with adverse events (AE). While low or non-existent drug levels and positive antidrug antibodies have been associated with therapeutic failure, there is no clear association between higher drug levels and AE. A cross-sectional study consisting of Crohn’s disease (CD) and ulcerative colitis (UC) patients receiving infliximab or vedolizumab at the Sheba Medical Center was performed. Patien...
Source
Source